Aurora seems to have a pretty high interest in Australia, and in order to launch a new medical cannabis brand called CraftPlant, it has decided to join forces with MedReleaf Australia. The Canadian company believes it has a strong opportunity on the other side of the world and is looking to bring its quality to all those patients looking to benefit from the effects of cannabis.
MedReleaf Australia and Aurora announced yesterday a new partnership to launch CraftPlant, a new brand of medical marijuana for patients in the Australian market. The brand will bring to market three new products (Greendae, Navana and HiVolt) that can be used in doctors’ prescriptions. The trio of products will be developed from high-quality THC-dominant cultivars with high percentages of terpenes.
The ultra-premium cultivars were developed by Aurora’s leading science and genetics company, Occo. The companies have emphasized that the new product range has been produced under strict EU-GMP-certified conditions and will be available in 10g packs.
“Through our partnership with MedReleaf Australia, we are proud to continue to lead the way in the Australian market with the addition of new and innovative products for patients,” says Miguel Martin, CEO of Aurora Cannabis. “As we build on our strategic international growth plans, Australia has proven to be a very promising and sustainable cannabis market that we are committed to.”
The Canadian-based firm has a 10% stake in MedReleaf Australia, so this partnership comes as no surprise to many in the industry. For some time now, the two organizations have been working hand-in-hand to provide patients in the Oceanic country with access to various Aurora-branded products, including dried flowers, oils, and soft gels.